Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Matinas BioPharma (MTNB)
NYSE MKT:MTNB
Matinas BioPharma (MTNB) Stock Price & Analysis
1,334 Followers
MTNB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.39 - $1.00
Previous Close$0.41
Volume185.73K
Average Volume (3M)297.93K
Market Cap
$93.42M
Enterprise Value$64.85M
Total Cash (Recent Filing)$28.76M
Total Debt (Recent Filing)$4.12M
Price to Earnings (P/E)-4.2
Beta1.21
Next Earnings
May 11, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding216,864,526
10 Day Avg. Volume256,503
30 Day Avg. Volume297,933
Standard Deviation0.30
R-Squared0.14
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)3.18
Price to Sales (P/S)51.33
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-6.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue20.34
Enterprise Value/Gross Profit-4.81
Enterprise Value/Ebitda-2.74
Forecast
1Y Price Target
$3.00Price Target Upside597.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Matinas BioPharma News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MTNB FAQ
What was Matinas BioPharma’s price range in the past 12 months?
Matinas BioPharma lowest stock price was $0.39 and its highest was $1.00 in the past 12 months.
What is Matinas BioPharma’s market cap?
Currently, no data Available
When is Matinas BioPharma’s upcoming earnings report date?
Matinas BioPharma’s upcoming earnings report date is May 11, 2023 which is in 50 days.
How were Matinas BioPharma’s earnings last quarter?
Matinas BioPharma released its earnings results on Mar 15, 2023. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.025 by $0.005.
Is Matinas BioPharma overvalued?
According to Wall Street analysts Matinas BioPharma’s price is currently Undervalued.
Does Matinas BioPharma pay dividends?
Matinas BioPharma does not currently pay dividends.
What is Matinas BioPharma’s EPS estimate?
Matinas BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Matinas BioPharma have?
Matinas BioPharma has 217,264,530 shares outstanding.
What happened to Matinas BioPharma’s price movement after its last earnings report?
Matinas BioPharma reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.025. Following the earnings report the stock price went up 6.977%.
Which hedge fund is a major shareholder of Matinas BioPharma?
Currently, no hedge funds are holding shares in MTNB
---
Matinas BioPharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.00 (597.67% Upside)
$3.00 (597.67% Upside)
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.91%
12-Months-Change
Fundamentals
Return on Equity
-47.12%
Trailing 12-Months
Asset Growth
28.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Matinas BioPharma
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded in May 2013 and is headquartered in Bedminster, NJ.
---
Oric Pharmaceuticals
―
Anixa Biosciences
―
Alaunos Therapeutics
―
Precision BioSciences
―
VBI Vaccines
―
---